ClinicalTrials.gg
CompletedNCT00150800Updated Aug 17, 2021Results posted

This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment

A Phase 3 interventional study of Brivaracetam in Epilepsy, sponsored by UCB PHARMA Inc. (US). Completed at 100 sites in 6 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by UCB PHARMA Inc. (US) (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
668
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
4th of 34
668 · median 94
Started
2006
the only one that year
Phase 3
21 of 34
1 open now
Registered
1st of 34
by date
Lead sponsor
1 of 34
UCB PHARMA Inc. (US)

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 4th largest by enrollment, is the only one that started in 2006, is one of 21 in phase 3, and was the 1st registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 282 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This trial, evaluating the long-term safety and tolerability of brivaracetam will provide subjects suffering from epilepsy, who may have benefited from brivaracetam as adjunctive treatment, the opportunity to receive open label brivaracetam treatment.

Read the detailed description

Study access was limited to subjects having completed one of the previous brivaracetam (BRV) studies: N01193 [NCT00175825], N01252 [NCT00490035], N01253 [NCT00464269], N01254 [NCT00504881].

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Epilepsy
  • Partial Onset Seizures
  • open label
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/ female subjects from 16 years and on. Subjects under 18 years may only be included where legally permitted and ethically accepted
  • Subjects with epilepsy who have participated in previous brivaracetam trials which allow access to the present study
  • Subjects for whom the investigator believes a reasonable benefit from the long term administration of brivaracetam may be expected
  • Female subjects without . Female subjects with child bearing potential are eligible if they use a medically accepted method for the duration of the study
  • Subject/ legally acceptable representative considered as reliable and capable of adhering to the protocol, visit schedule or medication intake according to the judgment of the Investigator

Exclusion criteria

Exclusion Criteria:

  • Severe medical, neurological and psychiatric disorders or laboratory values which may have an impact on the safety of the subject
  • Poor compliance with the visit schedule or medication intake in the previous brivaracetam study
  • Pregnant or lactating women
  • Participation in any clinical study of another drug or device during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
668 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Brivaracetam used as adjunctive treatment, flexible dosing up to 200 mg /day in b.i.d (twice daily) administration. Dose increase or decrease can be made in increments of maximum 50 mg/day on a weekly basis.

    Drug: Brivaracetam

Interventions

  • * Active Substance: Brivaracetam * Pharmaceutical Form: Tablet * Concentration: 10 mg and 25 mg * Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period

    Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

    Time frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)

  2. Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Period

    Adverse Events (AE) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

    Time frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)

  3. Percentage of Participants With a Serious Adverse Event (SAE) During the Study Period

    A Serious Adverse Event (SAE) is any untoward medical incidence that occurs at any dose.

    Time frame: Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)

Secondary outcomes

  1. Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period

    Baseline is the Baseline from subject's previous study of enrollment period. N01193 \[NCT00175825\], N01252 \[NCT00490035\], N01253 \[NCT00464269\], N01254 \[NCT00504881\]. A 28 day Type 1 seizure frequency is the total number of Type 1 seizures divided by the total number of days evaluated multiplied by 28.

    Time frame: From Baseline of the previous study to the Evaluation Period (up to 11 years)

  2. Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period

    The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines.

    Time frame: From Baseline of the previous study to the Evaluation Period (up to 11 years)

  3. Percentage of Participants With Response for Partial Onset Seizure (POS) (Type I) Frequency Over the Evaluation Period

    A responder is defined as a subject with a higher than or equal to (\>=) 50 % change in seizure frequency from Baseline period of the previous study.

    Time frame: From Baseline of the previous study to the Evaluation Period (up to 11 years)

07

Results

Posted Dec 5, 2018

Participant flow

The study started to enroll patients in January 2006 and concluded in September 2017. 668 subjects were included in the Enrolled Set but 1 subject from India lost to follow up and was excluded from the Safety Analysis Set due to lack of medical data.

Participant flow — Overall Study
MilestoneBrivaracetam
Started667
Completed171
Not completed496
Withdrew: Adverse event89
Withdrew: Death18
Withdrew: Lack of efficacy166
Withdrew: Lost to follow-up58
Withdrew: Subject's choice90
Withdrew: No compliance18
Withdrew: Ip misshandling1
Withdrew: Site closure24
Withdrew: Protocol non-adherence2
Withdrew: Nobody to accompany patient1
Withdrew: Distance too long for patient1
Withdrew: Neurosurgery2
Withdrew: Brv monotherapy1
Withdrew: Visit refusal3
Withdrew: Sponsor's request2
Withdrew: Generalized epilepsy1
Withdrew: Moved from area/country8
Withdrew: Pi retiring2
Withdrew: Pi leaving site2
Withdrew: Patient insurance1
Withdrew: Surgical intervention4
Withdrew: Pregnancy planned1
Withdrew: Pi discontinuation request1

Outcome measures

PrimaryPercentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period

Treatment-Emergent Adverse Events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

Time frame:
Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period
percentage of participantsBrivaracetam (SS)
Percentage of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) During the Study Period91.2
PrimaryPercentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Period

Adverse Events (AE) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

Time frame:
Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Period
percentage of participantsBrivaracetam (SS)
Percentage of Participants Who Withdrew Due to an Adverse Event (AE) During the Study Period14.8
PrimaryPercentage of Participants With a Serious Adverse Event (SAE) During the Study Period

A Serious Adverse Event (SAE) is any untoward medical incidence that occurs at any dose.

Time frame:
Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years)
Reported as:
Number · percentage of participants
Percentage of Participants With a Serious Adverse Event (SAE) During the Study Period
percentage of participantsBrivaracetam (SS)
Percentage of Participants With a Serious Adverse Event (SAE) During the Study Period22.8
SecondaryPartial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period

Baseline is the Baseline from subject's previous study of enrollment period. N01193 \[NCT00175825\], N01252 \[NCT00490035\], N01253 \[NCT00464269\], N01254 \[NCT00504881\]. A 28 day Type 1 seizure frequency is the total number of Type 1 seizures divided by the total number of days evaluated multiplied by 28.

Time frame:
From Baseline of the previous study to the Evaluation Period (up to 11 years)
Reported as:
Median · Seizures per 28 days
Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period
Seizures per 28 daysBrivaracetam (POS-ES)
baseline9.2 (5.5 to 20.2)
on treatment4.2 (1.6 to 11.3)
SecondaryPercent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period

The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines.

Time frame:
From Baseline of the previous study to the Evaluation Period (up to 11 years)
Reported as:
Median · percent change
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period
percent changeBrivaracetam (POS-ES)
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period57.3 (18.6 to 82.2)
SecondaryPercentage of Participants With Response for Partial Onset Seizure (POS) (Type I) Frequency Over the Evaluation Period

A responder is defined as a subject with a higher than or equal to (\>=) 50 % change in seizure frequency from Baseline period of the previous study.

Time frame:
From Baseline of the previous study to the Evaluation Period (up to 11 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Response for Partial Onset Seizure (POS) (Type I) Frequency Over the Evaluation Period
percentage of participantsBrivaracetam (POS-ES)
Percentage of Participants With Response for Partial Onset Seizure (POS) (Type I) Frequency Over the Evaluation Period55.6

Adverse events

Collected over Visit 1 through last Evaluation Period, Down-Titration, or Post-Treatment Periods (up to 11 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam18/667 (2.7%)152/667 (22.8%)521/667 (78.1%)
Most frequent serious events
Showing 10 of 173
Most frequent serious events
EventBrivaracetam
ConvulsionNervous system disorders15/667
PneumoniaInfections and infestations7/667
Suicide attemptPsychiatric disorders7/667
Status epilepticusNervous system disorders6/667
PregnancyPregnancy, puerperium and perinatal conditions5/667
Toxicity to various agentsInjury, poisoning and procedural complications4/667
Transient ischaemic attackNervous system disorders4/667
Myocardial infarctionCardiac disorders3/667
Unevaluable eventGeneral disorders3/667
Urinary tract infectionInfections and infestations3/667
Most frequent other events
Showing 10 of 31
Most frequent other events
EventBrivaracetam
HeadacheNervous system disorders165/667
DizzinessNervous system disorders142/667
NasopharyngitisInfections and infestations94/667
SomnolenceNervous system disorders91/667
InfluenzaInfections and infestations84/667
Upper respiratory tract infectionInfections and infestations76/667
ConvulsionNervous system disorders70/667
DepressionPsychiatric disorders70/667
PyrexiaGeneral disorders69/667
NauseaGastrointestinal disorders67/667

Baseline characteristics

The Baseline Characteristics refers to the Safety Analysis Set which included all subjects who took at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years30
Between 18 and 65 years632
>=65 years5
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean34.3 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female303
Male364
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brivaracetam
American Indian/Alaskan Native21
Asian206
Black18
Native Hawaiian Or Other Pacific Islander1
White361
Other/Mixed60
08

Study locations

100 sites
  • N01199 1051
    Phoenix, Arizona, United States
  • N01199 1362
    Phoenix, Arizona, United States
  • N01199 1374
    Tucson, Arizona, United States
  • N01199 1050
    Little Rock, Arkansas, United States
  • N01199 1078
    Fresno, California, United States
  • N01199 1392
    Newport Beach, California, United States
  • N01199 1087
    San Francisco, California, United States
  • N01199 1368
    San Francisco, California, United States
  • N01199 1396
    Atlanta, Georgia, United States
  • N01199 1385
    Augusta, Georgia, United States
  • N01199 1356
    Chicago, Illinois, United States
  • N01199 1388
    Springfield, Illinois, United States
  • N01199 1375
    Wichita, Kansas, United States
  • N01199 1364
    Lexington, Kentucky, United States
  • N01199 1380
    Louisville, Kentucky, United States
  • N01199 1052
    Paducah, Kentucky, United States
  • N01199 1083
    Ruston, Louisiana, United States
  • N01199 1373
    Baltimore, Maryland, United States
  • N01199 1086
    Bethesda, Maryland, United States
  • N01199 1077
    Burlington, Massachusetts, United States
  • N01199 1391
    Detroit, Michigan, United States
  • N01199 1395
    Detroit, Michigan, United States
  • N01199 1071
    Grand Rapids, Michigan, United States
  • N01199 1389
    Saint Paul, Minnesota, United States
  • N01199 1079
    Tupelo, Mississippi, United States
  • N01199 1360
    Chesterfield, Missouri, United States
  • N01199 1352
    Saint Louis, Missouri, United States
  • N01199 1069
    Great Falls, Montana, United States
  • N01199 1062
    Toms River, New Jersey, United States
  • N01199 1053
    New York, New York, United States
  • N01199 1365
    Rochester, New York, United States
  • N01199 1366
    Cincinnati, Ohio, United States
  • N01199 1054
    Columbus, Ohio, United States
  • N01199 1359
    Portland, Oregon, United States
  • N01199 1055
    Philadelphia, Pennsylvania, United States
  • N01199 1059
    Philadelphia, Pennsylvania, United States
  • N01199 1081
    Greenville, South Carolina, United States
  • N01199 1061
    Nashville, Tennessee, United States
  • N01199 1084
    Dallas, Texas, United States
  • N01199 1394
    Dallas, Texas, United States
  • N01199 1064
    Houston, Texas, United States
  • N01199 1082
    Salt Lake City, Utah, United States
  • N01199 1367
    Charlottesville, Virginia, United States
  • N01199 1393
    Richmond, Virginia, United States
  • N01199 1376
    Seattle, Washington, United States
  • N01199 1369
    Milwaukee, Wisconsin, United States
  • N01199 1420
    Chatswood, New South Wales, Australia
  • N01199 1430
    Randwick, New South Wales, Australia
  • N01199 1423
    Adelaide, South Australia, Australia
  • N01199 1428
    Woodville, South Australia, Australia
  • N01199 1427
    Clayton, Victoria, Australia
  • N01199 1426
    Parkville, Victoria, Australia
  • N01199 1421
    West Heidelberg, Victoria, Australia
  • N01199 1422
    Fitzroy, Australia
  • N01199 1028
    Campinas, Brazil
  • N01199 1325
    Curitiba, Brazil
  • N01199 1024
    Florianopolis, Brazil
  • N01199 1150
    Florianópolis, Brazil
  • N01199 1331
    Porto Alegre, Brazil
  • N01199 1332
    Porto Alegre, Brazil
  • N01199 1022
    Riberao Preto, Brazil
  • N01199 1023
    Salvador, Brazil
  • N01199 1021
    Sao Paulo, Brazil
  • N01199 1027
    Sao Paulo, Brazil
  • N01199 1030
    Sao Paulo, Brazil
  • N01199 1326
    Sao Paulo, Brazil
  • N01199 1029
    São José do Rio Preto, Brazil
  • N01199 1316
    Edmonton, Alberta, Canada
  • N01199 1312
    Greenfield Park, Quebec, Canada
  • N01199 1311
    Montreal, Quebec, Canada
  • N01199 1314
    Montreal, Quebec, Canada
  • N01199 1313
    Quebec City, Quebec, Canada
  • N01199 1266
    Mumbai, Maharashti, India
  • N01199 1045
    Bangalore, India
  • N01199 1256
    Bangalore, India
  • N01199 1257
    Bangalore, India
  • N01199 1261
    Bangalore, India
  • N01199 1046
    Chennai, India
  • N01199 1042
    Hyderabad, India
  • N01199 1253
    Hyderabad, India
  • N01199 1262
    Hyderabad, India
  • N01199 1258
    Jaipur, India
  • N01199 1040
    Lucknow, India
  • N01199 1250
    Lucknow, India
  • N01199 1043
    Mumbai, India
  • N01199 1259
    Mumbai, India
  • N01199 1265
    Parel Mumbai, India
  • N01199 1264
    Pune Maharashtra, India
  • N01199 1251
    Pune, India
  • N01199 1263
    Tirupati, India
  • N01199 1412
    San Nicholas De Los Garza, Nuevo Leon, Mexico
  • N01199 1010
    Aguascalientes, Mexico
  • N01199 1008
    Chihuahua, Mexico
  • N01199 1009
    Chihuahua, Mexico
  • N01199 1003
    Guadalajara, Mexico
  • N01199 1403
    Mexico City, Mexico
  • N01199 1005
    Monterrey, Mexico
  • N01199 1007
    Monterrey, Mexico
  • N01199 1002
    San Luis Potosi, Mexico
  • N01199 1001
    Zapopan, Mexico
09

References and documents

Publications

  • O'Brien TJ, Borghs S, He QJ, Schulz AL, Yates S, Biton V. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial. Epilepsia. 2020 Apr;61(4):636-646. doi: 10.1111/epi.16484. Epub 2020 Mar 28. PubMed 32221987 ↗
  • Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis. Epilepsy Res. 2021 Oct;176:106694. doi: 10.1016/j.eplepsyres.2021.106694. Epub 2021 Jun 24. PubMed 34218211 ↗
  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Sep 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2018, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Jan 2006
Primary completionActual
Sep 2017
CompletionActual
Sep 2017
Results first posted
Dec 5, 2018
Last update
Aug 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00150800
Responsible party
Sponsor
First posted
Sep 8, 2005
Start date
Jan 2006
Primary completion
Sep 2017
Completion
Sep 2017
Results posted
Dec 5, 2018
Last update
Aug 17, 2021

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion